

HR 4404

Depression Side Effect Labeling Awareness Act of 2019

Congress: 116 (2019–2021, Ended)

Chamber: House

Policy Area: Health

Introduced: Sep 19, 2019

Current Status: Referred to the Subcommittee on Health.

Latest Action: Referred to the Subcommittee on Health. (Sep 20, 2019)

Official Text: <https://www.congress.gov/bill/116th-congress/house-bill/4404>

Sponsor

Name: Rep. Rush, Bobby L. [D-IL-1]

Party: Democratic • **State:** IL • **Chamber:** House

Cosponsors (7 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Jackson Lee, Sheila [D-TX-18]	D · TX		Sep 25, 2019
Rep. Dingell, Debbie [D-MI-12]	D · MI		Oct 4, 2019
Rep. Carson, Andre [D-IN-7]	D · IN		Nov 12, 2019
Rep. Wild, Susan [D-PA-7]	D · PA		Dec 4, 2019
Rep. Thompson, Bennie G. [D-MS-2]	D · MS		Dec 9, 2019
Rep. Hastings, Alcee L. [D-FL-20]	D · FL		Jan 21, 2020
Del. San Nicolas, Michael F. Q. [D-GU-At Large]	D · GU		Jul 21, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Sep 20, 2019

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of Sep 19, 2019)

Depression Side Effect Labeling Awareness Act of 2019

This bill specifies that, if a drug's label indicates an increased risk of suicide or depression, this information must be displayed prominently.

Actions Timeline

- **Sep 20, 2019:** Referred to the Subcommittee on Health.
- **Sep 19, 2019:** Introduced in House
- **Sep 19, 2019:** Referred to the House Committee on Energy and Commerce.